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Abstract
Dengue is a major public health problem worldwide and continues to increase in incidence. Dengue virus (DENV) infection
leads to a range of outcomes, including subclinical infection, undifferentiated febrile illness, Dengue Fever (DF), life-
threatening syndromes with fluid loss and hypotensive shock, or other severe manifestations such as bleeding and organ
failure. The long-standing World Health Organization (WHO) dengue classification and management scheme was recently
revised, replacing DF, Dengue Hemorrhagic Fever (DHF), and Dengue Shock Syndrome (DSS) with Dengue without Warning
Signs, Dengue with Warning Signs (abdominal pain, persistent vomiting, fluid accumulation, mucosal bleeding, lethargy,
liver enlargement, increasing hematocrit with decreasing platelets) and Severe Dengue (SD; dengue with severe plasma
leakage, severe bleeding, or organ failure). We evaluated the traditional and revised classification schemes against clinical
intervention levels to determine how each captures disease severity using data from five years (2005–2010) of a hospital-
based study of pediatric dengue in Managua, Nicaragua. Laboratory-confirmed dengue cases (n=544) were categorized
using both classification schemes and by level of care (I–III). Category I was out-patient care, Category II was in-patient care
that did not meet criteria for Category III, which included ICU admission, ventilation, administration of inotropic drugs, or
organ failure. Sensitivity and specificity to capture Category III care for DHF/DSS were 39.0% and 75.5%, respectively;
sensitivity and specificity for SD were 92.1% and 78.5%, respectively. In this data set, DENV-2 was found to be significantly
associated with DHF/DSS; however, this association was not observed with the revised classification. Among dengue-
confirmed cases, the revised WHO classification for severe dengue appears to have higher sensitivity and specificity to
identify cases in need of heightened care, although it is no longer as specific for a particular pathogenic entity as was the
traditional schema.
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Introduction
Dengue is an arthropod-borne viral disease with increasing
prevalence in the last three decades, resulting in serious public
health problems worldwide. With no vaccine or specific
treatment to mitigate the natural history of the disease, a tool
that can help clinicians detect and provide timely treatment is of
utmost importance. The traditional World Health Organization
(WHO) classification for dengue was implemented since 1974,
based on experience with pediatric dengue in Thailand, and was
then revised in 1997 [1,2]. It classifies dengue disease as Dengue
Fever (DF), Dengue Hemorrhagic Fever (DHF), and Dengue
Shock Syndrome (DSS). The case definition for DHF lists the
presence of four criteria: fever, hemorrhagic manifestations,
thrombocytopenia (platelets #100,000 cells/mm
3), and evidence
of plasma leakage (pleural effusion, ascites, hemoconcentration
$20% or hypoproteinemia). In turn, DHF is divided into four
grades (DHF I–IV), where Grades III and IV are DSS, with
hypotensive shock or narrow pulse pressure plus clinical signs of
shock. It has proved to be very useful, with an emphasis on
volume replacement for hemodynamic instability. However,
limitations have been noted regarding its complexity and
applicability, particularly in patients with severe symptoms
[3,4,5,6,7,8]. The recognition of these limitations led the Tropical
Disease Reseach branch (TDR) of the WHO in 2006–7 to
sponsor a multicenter study in seven countries in Asia and Latin
America [9], and from this study emerged a new classification
schema [10]. The new classification is divided into Dengue
without Warning Signs, Dengue with Warning Signs, and Severe
Dengue. In this study, we evaluated the capacity of the traditional
classification and the revised classification to detect severe cases of
dengue, compared to standardized clinical intervention levels.
This evaluation was performed with information from ,550
laboratory-confirmed dengue patients 6 months to 14 years old
seen at the National Pediatric Reference Hospital in Managua,
Nicaragua, from 2005 to 2010.
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Study Site and Population
A cross-sectional study was performed in the Hospital Infantil
Manuel de Jesu ´s Rivera (HIMJR), the National Pediatric Reference
Hospital, in Managua, Nicaragua. A total of 544 children who
attended the HIMJR between July 2005 and January 2010 with
laboratory-confirmed dengue were studied. These patients were
between 6 months and 14 years of age, had fever or history of fever
less than 7 days, and one or more of the following signs and
symptoms: headache, arthralgia, myalgia, retro-orbital pain,
positive tourniquet test, petechiae, or signs of bleeding. Patients
with a defined focus other than dengue were excluded. Additional
exclusion criteria included: a) children weighing less than 8 kg, b)
children lessthan 6 monthsofage,andc)children6 years ofageand
older displaying signs of altered consciousness at the time of
recruitment. Patient data such as vital signs, clinical data, and
radiographic or ultrasound results were collected on a daily basis by
trained medical personnel until discharge. A blood sample was
collected daily for a minimum of three days for Complete Blood
Count (CBC) with platelets, blood chemistry, and diagnostic tests
for dengue. Between days 14 and 21 after onset of symptoms, a
blood sample was taken for convalescent follow-up. Hospital
admission criteria for study participants is detailed in Text S1.
Criteria for admission to the Intensive Care Unit (ICU) included
patients with shock despite appropriate fluid management with
crystalloids and colloids, patients requiring vasoactive amines,
patients using a mechanical ventilator, or patients requiring
continuous monitoring due to hemodynamic instability. Over the
years,a few patients were not able tobe admitted to the ICUdespite
meeting ICU admission criteria due to the lack of space in the ICU.
Ethics Statement
The protocol for this study was reviewed and approved by the
Institutional Review Boards (IRB) of the University of California,
Berkeley, and of the Nicaraguan Ministry of Health. Parents or
legal guardians of all subjects provided written informed consent,
and subjects 6 years of age and older provided assent.
Data Management
All information was collected every 12 hours in Case Report
Forms (CRFs) designed to follow the patients’ progress. Each CRF
was completed by an infectious disease pediatrician and supervised
by a second physician. Following this supervision, the CRFs were
systematically monitored and then their information was entered
into an Access 2003 database by double-date entry, with quality
control checks performed daily and weekly. Thus, all data were
collected prospectively over the entire course of illness following
the same protocol and were reviewed carefully in real time to
minimize any missing data. The data were then analyzed by illness
episode; there were no missing signs or symptoms by episode.
Dengue Diagnosis
A case was considered positive for dengue when laboratory tests
met one or more of the following criteria: 1) Dengue viral RNA
was detected by RT-PCR, 2) Dengue virus (DENV) was isolated,
3) Seroconversion of DENV-specific IgM was detected by MAC-
ELISA in paired acute and convalescent samples, and 4) DENV-
specific antibody titer by Inhibition ELISA [11,12,13] demon-
strated a 4-fold or greater increase between acute and convalescent
sera. Primary DENV infections were those in which acute
antibody titer was ,10 or convalescent antibody titer was
,2,560, and secondary infections were those in which antibody
titer was $10 (acute) or $2,560 (convalescent) as determined by
Inhibition ELISA.
WHO Classifications
The traditional WHO classification is defined as follows:
Dengue Fever (DF), Dengue Hemorrhagic Fever (DHF), and
Dengue Shock Syndrome (DSS), whereas the revised WHO
classification consists of Dengue without Warning Signs, Dengue
with Warning Signs, and Severe Dengue (Table 1). Regarding the
traditional classification, laboratory-confirmed cases that met the
case definition for dengue but did not comply with the criteria for
DHF or DSS were classified as DF. With respect to the revised
classification, we interpreted SD to include compensated shock
based on dengue case management algorithms in the 2009 WHO
Guidelines [10]. A computerized algorithm was developed to
classify laboratory-confirmed dengue patients according to the
traditional and revised classifications; this algorithm compiled the
presence or absence of all signs and/or symptoms as well as results
of clinical laboratory tests and radiography/ultrasound and
thereby determined the level of severity according to each of the
classifications (Table S1).
The following definitions were used for each of the warning
signs: Abdominal pain: abdominal tenderness and continuous pain
(not intermitent), on some occasions diffuse. Persistent vomiting:
more than three episodes of vomiting in 12 hours, preventing
adequate oral hydration.
Clinical accumulation of liquids: pleural effusion and ascites
diagnosed clinically, confirmed with imaging techniques (ultra-
sound for ascites, gallbladder wall thickening, and pleural effusion,
and/or X-rays for pleural effusion). Mucosal bleeding: bleeding
gums or conjunctiva, epistaxis, vaginal bleeding, bleeding from
digestive, respiratory or urinary system (kidneys); mucosa defined
as respiratory, vaginal, digestive, conjunctival and urinary tract
mucosa. Lethargy: evaluated as an alteration of consciousness with
a Glasgow score less than 15 or a Blantyre score less than 5.
Irritability: irritability or restlessness. Hepatomegaly: the liver edge
Author Summary
Dengue is a mosquito-transmitted viral disease that is a
major public health problem worldwide. Dengue virus
(DENV) infection leads to Dengue Fever (DF) and a
spectrum of life-threatening syndromes with fluid loss
and hypotensive shock or other severe manifestations.
Recently, the traditional World Health Organization (WHO)
dengue classification scheme (classic DF, Dengue Hemor-
rhagic Fever (DHF), and Dengue Shock Syndrome (DSS))
was replaced with Dengue without Warning Signs, Dengue
with Warning Signs and Severe Dengue (SD). Using data
from 544 laboratory-confirmed dengue cases recruited
over five years of a hospital-based study of pediatric
dengue in Managua, Nicaragua, we evaluated the tradi-
tional and revised classification schemes against clinical
intervention levels (I–III) to determine how each captures
disease severity. The sensitivity and specificity to capture
Category III care for DHF/DSS were 39.0% and 75.5%,
respectively, and for SD were 92.1% and 78.5%, respec-
tively. Interestingly, DENV-2 was significantly associated
with DHF/DSS; however, this association was not observed
with the revised classification. This study indicates that
among dengue-confirmed cases, the revised WHO classi-
fication appears to have higher sensitivity and specificity
for identifying cases in need of heightened care, although
it is no longer as specific for a particular pathogenic entity
as was the traditional schema.
Evaluation of WHO Dengue Classification Schemes
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Previous WHO Classification for Dengue Severity
Dengue Fever (DF)
Acute febrile illness with two or more of the following:
N Headache
N Retro-orbital pain
N Myalgia
N Leukopenia
N Arthralgia
N Rash
N Hemorrhagic manifestations
N Supportive serology or occurrence at the same location and time as other confirmed cases of dengue fever.
Dengue Hemorrhagic Fever (DHF)
All of the following must be present:
N Fever or history of acute fever, lasting 2–7 days, occasionally biphasic.
N Hemorrhagic manifestations:
– Positive torniquet test;
– Petechia, equimosis, purpura or bleeding from mucosa, gastrointestinal tract, injection sites or other locations; or
– Haematemesis/melena.
N Thrombcytopenia (,100,000 platelets per mm
3).
N Evidence of plasma leakage due to increased vascular permeability.
Dengue Shock Syndrome (DSS)
DHF with hypotension for age or narrow pulse pressure (,20 mmHg), plus one of the following:
N Rapid and weak pulse
N Cold, clammy skin, restlessness
Revised WHO Classification for Dengue Severity
Dengue without Warning Signs
Fever and two of the following:
N Nausea, vomiting
N Rash
N Aches and pains
N Leukopenia
N Positive torniquet test
Dengue with Warning Signs
Dengue as defined above with any of the following:
N Abdominal pain or tenderness
N Persistent vomiting
N Clinical fluid accumulation
N Mucosal bleeding
N Lethargy, restlessness
N Liver enlargement .2c m
N Laboratory: increase in HCT concurrent with rapid decrease in platelet count
Severe Dengue
Dengue with at least one of the following criteria:
N Severe Plasma Leakage leading to:
– Shock (DSS)
– Fluid accumulation with respiratory distress
N Severe Bleeding as evaluated by clinician
N Severe organ involvement
– Liver: AST or ALT$1000
– CNS: impaired consciousness
– Failure of heart and other organs
doi:10.1371/journal.pntd.0001397.t001
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Increased hematocrit concurrent with rapid decrease in platelet
count: increase in hematocrit together with a decrease of .10,000
platelets/mm
3 in 24 hours with respect to previous measurement
or concurrent with platelet count #100,000 cells/mm
3.
Statistical Analysis
The level of agreement for detection of severe cases of dengue
between the traditional and revised classifications was determined
using the Kappa index, as was the concordance between the
clinical diagnosis by the physicians and the diagnosis generated by
the computer algorithm. A Kappa value ,0.00 was considered
‘‘poor agreement,’’ 0.00–0.20 as ‘‘slight agreement,’’ 0.21–0.40 as
‘‘fair agreement,’’ 0.41–0.60 as ‘‘moderate agreement,’’ 0.61–0.80
as ‘‘substantial agreement,’’ and 0.81–0.99 as ‘‘almost perfect
agreement’’ [14]. To determine the sensitivity, specificity, and
positive and negative predictive values of the traditional and
revised WHO classifications for the detection of severe cases of
dengue, each classification schema was compared to standardized
clinical intervention levels. Three reference levels (gold standard)
were established based on the type of intervention the patient
required in accordance with the DENCO study sponsored by
TDR [9]. Category I were those patients who were managed as
outpatients (did not present criteria for hospitalization). Category II
were hospitalized patients who received intravenous fluids for
rehydration or maintanance and did not suffer organ damage.
Category III were patients hospitalized in the Intensive Care Unit
(ICU), administered inotropic drugs or ventilation, or who
experienced organ failure. Patients classified as DHF or DSS
were considered severe, and those classified as DF were considered
non-severe. In the case of the revised WHO classification, patients
classified as Severe Dengue were considered severe, and those with
Dengue with or without Warning Signs were considered non-
severe. With respect to the reference levels, severe dengue cases
were considered as patients managed with Category III care. All
data was stored in Microsoft Office Access version 2003 and
analyzed using Stata Intercooled 9.0 (StataCorp LP, College
Station, Texas), with a 95% confidence level.
Results
Of 901 suspected dengue cases, 544 (60.4%) were laboratory-
confirmed as positive. Within these 544 laboratory-confirmed
dengue cases, sex was found to be evenly distributed (50% female,
50% male). Age varied between 6 months and 14 years, with a
median of 8.5 years (IQR 5.1–11.2 years), and 40.6% between 5
and 9 years of age. Immune response was determined in 525
patients, of which 309 (58.9%) presented a secondary immune
response. DENV serotype was identified in 494 (90.8%) patients,
with DENV-3 predominating in 287 (58.1%) of the cases,
followed by DENV-2 in 161 (32.6%) and DENV-1 in 45 (9.1%)
(Table 2).
Evaluation of the Classifications
According to the traditional WHO classification, the majority of
the patients were classified as DF (385; 70.8%), while the
remaining 29.2% were divided between DHF (106; 19.5%) and
DSS (53; 9.7%). In contrast, with the revised scheme, although the
majority of cases were classified as Dengue with Warning Signs
(266; 48.9%), a large percentage of patients were classified as
Severe Dengue (242; 44.5%) and only a small percentage (36;
6.6%) were classified as Dengue without Warning Signs (Figure 1).
The level of agreement between the traditional and revised
classifications for the detection of severe cases of dengue was fair
(kappa 0.25, CI95% 0.17–0.32, p,0.001) (Table 3), and the
percentage of observed agreement (64.1%) was somewhat higher
than that expected by chance alone (52.3%).
In the traditional classification, the majority of DF cases were
treated at Category II, as they were hospitalized and received some
type of intravenous (IV) rehydration. However, it is striking that
28.1% (108/385) of these patients received Category III interven-
tion, as, despite being classified as DF, they showed severe clinical
manifestations warranting ICU transfer or administration of
inotropic drugs (Table 4). Ninety percent (48/53) of DSS cases
were managed according to Category III care. However, most DHF
cases (76.4%; 81/106) were treated at Category II care, and as such,
sensitivity for detecting severe cases of dengue (DHF/DSS) was
low (39.0%, CI95% 31.8–46.6) and specificity was moderate
(75.5%, 70.7–79.8) (Table 4).
When the revised classification was compared with level of care
(as the gold standard), 61.1% (22/36) of patients with Dengue
without Warning Signs were treated as outpatients (Category I). In
38.9% (14/36) of remaining cases, 36.1% (13/36) fell under
Category II care, and only one patient classified as Dengue without
Warning Signs received Category III care. Sixty-seven percent
(163/242) of Severe Dengue cases corresponded to Category III
care, although it is noteworthy that 8 children (3.3%) of those
classified as Severe Dengue were treated as outpatients (Category
I). The fact that Severe Dengue cases mostly fall under Category III
and non-severe cases of dengue (Dengue with and without
Warning Signs) are categorized as Category I and II allows for a
high level of sensitivity (92.1%, 87.1–95.6) and a moderate level
of specificity (78.5%, 73.9–82.6) for the detection of severe
dengue cases (Table 5). In this sense, the revised classification is
more sensitive than the traditional classification, but equally
specific.
Table 2. Demographic characteristics of study population,
2005–2010.
Demographic Characteristics N (%)
Suspected dengue 901
Laboratory-confirmed dengue 544 (60.4)
Other febrile illness 357 (39.6)
Age
a
,1 year 19 (3.5)
1 to 4 years 110 (22.2)
5 to 9 years 221 (40.6)
10 to 14 years 194 (35.7)
Sex
a
Female 272 (50)
Male 272 (50)
Immune response
a
Primary 216 (41.1)
Secondary 309 (58.9)
Dengue serotype
a
DENV-1 45 (9.1)
DENV-2 161 (32.6)
DENV-3 287 (58.1)
DENV-3 & DENV-4 1 (0.2)
aLaboratory-confirmed cases.
doi:10.1371/journal.pntd.0001397.t002
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In 2009, the concordance between the clinician’s diagnosis and
classification according to the algorithms was evaluated prospec-
tively (n=212). With respect to the traditional classification,
physicians had no difficulty classifying patients with DF or DSS,
which matched the diagnosis generated by the computer algorithm
in 95.6% (174/182), and 83.3% (5/6) of cases, respectively.
Difficulty was encountered in classifying DHF patients, however,
where only 12.5% (3/24) of cases were classified correctly, with
66.7% (16/24) being diagnosed as DSS by physicians. This
incongruence meant that the level of agreement between clinical
diagnosis and the computerized classification algorithm was
moderate (kappa=0.46, 0.38–0.55, p,0.001) (Table 6), with an
observed agreement (85.8%) higher than expected by chance
(73.6%).
When comparing the physicians’ clinical diagnosis with the
computer-generated algorithm of the revised WHO classification,
72.2% (13/18) of patients with Dengue without Warning Signs
and 87.8% (94/107) of patients with Severe Dengue were correctly
classified. A lower percentage of cases were correctly diagnosed in
those patients with Dengue with Warning Signs, where 66.7%
(58/87) of cases were correctly classified. The level of agreement
was substantial (kappa=0.62, 0.53–0.71, p,0.001) (Table 7), with
the observed agreement (77.8%) much higher than the expected
(41.3%). In general, it was found that physicians had fewer
difficulties classifying patients when using the revised classification
scheme.
During the study period, DENV-1, DENV-2, and DENV-3
circulated among the patients. Association of disease severity with
serotype was investigated using the two classification schemes.
Using the traditional WHO classification protocol, it was found
that the proportion of DHF and DSS cases was significantly
greater (p,0.001, Fisher’s exact test) in patients with DENV-2
infections as compared to the other serotypes (28.6% DHF and
22.3% DSS in DENV-2 infections versus 15.6% DHF and 11.1%
DSS in DENV-1 infections and 16.4% DHF and 3.8% DSS in
DENV-3 infections) (Table 8). Likewise, DENV-2 was most
associated with evidence of plasma leakage, such as ascites, pleural
effusion, and gallbladder wall thickening (p,0.001), as well as
thrombocytopenia (p,0.001) (Table S2). In contrast, no signifi-
cant difference between the proportion of severe cases and
serotype was observed when the revised classification was applied
(p=0.104, Fisher’s exact test), with 51.1%, 52.8% and 40.8% of
severe dengue in patients with DENV-1, DENV-2, and DENV-3
infections, respectively (Table 8).
Discussion
This study shows that the sensitivity and specificity of the
traditional WHO classification for the detection of severe cases of
dengue was 39.0% and 75.5%, respectively, while the sensitivity
and specificity of the revised classification was 92.1% and 78.5%,
respectively. A fair level of agreement (kappa=0.25, p,0.001) was
observed between the traditional and revised classifications for
detection of severe cases of dengue. Evaluation of physicians’
clinical diagnosis resulted in moderate agreement (kappa=0.46,
p,0.001) with the traditional classification and substantial
Figure 1. Traditional and revised WHO classification for dengue severity in Nicaraguan study, 2005–2010. The percentage of
laboratory-confirmed dengue cases classified as DF (n=385), DHF (n=106), or DSS (n=53) in the traditional scheme or classified as Dengue without
Warning Signs (n=36), Dengue with Warning Signs (n=266), or Severe Dengue (n=242) according to the revised scheme is shown.
doi:10.1371/journal.pntd.0001397.g001
Table 3. Concordance
a between Traditional and Revised
WHO classification in capturing severe cases of dengue, 2005–
2010.
Traditional
Classification Revised Classification Total
Dengue with/without
warning signs
Severe
Dengue
DF 246 139 385
DHF/DSS 56 103 159
Total 302 242 544
aKappa=0.25, CI95% 0.17–0.32, p,0.001.
doi:10.1371/journal.pntd.0001397.t003
Evaluation of WHO Dengue Classification Schemes
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However, whereas the traditional classification demonstrated a
significant association of DENV-2 infection with DHF/DSS, no
such association with Severe Dengue was observed with the
revised classification scheme.
The traditional WHO classification includes two major entities,
DF and DHF/DSS. This classification was largely based on
experience with a pediatric population in Southeast Asia, though
currently dengue has spread to other tropical and subtropical
regions and clinical presentation of the disease has changed.
Dengue varies widely in clinical manifestations, and the classifi-
cation of severity therefore depends on the presence and detection
of particular symptoms and signs. While the traditional classifica-
tion requires the presence of four criteria to qualify as a case of
DHF, situations have been observed where all four criteria are not
present, resulting in problems with the classification and detection
of severe cases. Indeed, many authors have reported difficulty in
complying with the traditional classification for documenting
clinical presentations of dengue such as hemorrhagic manifesta-
tions [4,15], thrombocytopenia [15,16,17,18,19], and fluid leakage
[4,15,20,21,22]. For instance, with respect to the latter, it is often
difficult to demonstrate that hemoconcentration is $20%, as there
are places where it is not possible to perform daily CBC; in
addition, a physician-ordered intervention during the course of the
illness, such as administration of intravenous fluids, can alter
hematocrit levels and thus hemoconcentration [15]. Another
complication is that few institutions in dengue-endemic countries
have records of a normal hematocrit value for each patient;
therefore, some investigators have used a population hematocrit
value as a baseline or the hematocrit value during the convalescent
phase or at discharge to define hemoconcentration via comparison
with the highest hematocrit observed during the acute phase of the
disease [4,17]. Use of a population baseline enables increased
documentation of plasma leakage, but may be less specific since
DENV-negative cases can present with elevated hematocrit [17];
whereas using the convalescent hematocrit value as baseline
requires retrospective classification of dengue cases.
Despite the widespread recognition of the usefulness of the
traditional classification, difficulties in documenting all of the
clinical manifestations required to define severe cases of dengue
has resulted in alternative designations of certain clinical
presentations seen in dengue, such as ‘‘Dengue with Signs
Associated with Shock’’ (DSAS) [13] and ‘‘Dengue with Severe
Bleeding’’ (DFB) [8]. As a result of this situation, Bandyopadhyay
[6] proposed the creation of a multicentric prospective study in
various countries of Asia and Latin America to describe the
varying clinical presentations of dengue and to determine whether
revision of the traditional WHO classification was necessary. Such
a study was conducted from 2006–2007, and from it emerged a
revised proposal for dengue classification [9]. Three levels of care
were used in this study as the reference or gold standard and were
based on the type of care needed and the condition in which
patients presented. Category III represented patients with a severe
condition and served as the comparison for DHF/DSS cases in the
traditional classification and Severe Dengue cases in the revised
classification. This methodology [9] was used as a basis for the
study reported here.
In our study, 71% of patients were classified as DF, 19.5% as
DHF, and only 9.7% as DSS according to the traditional
classification, while only 6.6% of patients were classified as
Dengue without Warning Signs, 48.9% as Dengue with Warning
Signs, and 44.5% as Severe Dengue according to the revised
Table 4. Traditional WHO classification of severity versus level of care, 2005–2010.
Traditional Classification Level of care Total
Category I Category II Category III
DF 83 194 108 385
DHF 4 81 21 106
DSS 0 5 48 53
Total 87 280 177 544
Sensitivity Specificity Positive predictive value Negative predictive value
39.0 (31.8–46.6) 75.5 (70.7–79.8) 43.4 (35.6–51.5) 71.9 (67.2–76.4)
doi:10.1371/journal.pntd.0001397.t004
Table 5. Revised WHO classification of severity versus level of care, 2005–2010.
Revised
Classification Level of care Total
Category I Category II Category III
Dengue without Warning Signs 22 13 1 36
Dengue with Warning Signs 57 196 13 266
Severe Dengue 8 71 163 242
Total 87 280 177 544
Sensitivity Specificity Positive predictive value Negative predictive value
92.1 (87.1–95.6) 78.5 (73.9–82.6) 67.4 (61.1–73.2) 95.4 (92.3–97.4)
doi:10.1371/journal.pntd.0001397.t005
Evaluation of WHO Dengue Classification Schemes
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between the two classification schemes can be explained by the
existence of 62 patients with hypotension for age who did not
present with platelet count #100,000, hemoconcentration or
hemorrhagic manifestations, and were thus classified as DF, and
101 patients with compensated shock who were also classified as
DF using the traditional scheme. These cases can serve to explain
the low sensitivity (39.0%) of this classification scheme for
detecting severe cases of dengue. The revised classification does
not require the presence of the four criteria to determine severity,
so the presence of shock, independent of thromobocytopenia or
hemoconcentration, is sufficient for a case to be designated severe,
and this explains the higher numbers of these cases within this
group of patients.
The high sensitivity of the revised classification (92.1%) for
detecting severe cases of dengue can be explained by the same
reason, that is, the presence of a single criterion for defining a
severe case. This feature allows better case capture and increased
admission to health units, though it results in not all cases being
truly ‘‘severe’’, as expressed by a moderate positive predictive
value (67.4%). This may overload health units in countries such as
Nicaragua where large numbers of patients are admitted, disease
evolution is carefully observed and monitored, and patients are
discharged slowly once cases of severe disease have been ruled out.
This over-estimation of severe cases of dengue may overwhelm
hospitals and health centers, particularly during outbreaks or
periods of high incidence, thus resulting in overextension of
medical personnel and resources of each unit, but would avoid
deaths due to the disease. In our pediatric cohort study of dengue
in Nicaragua, during the years 2004–2008, the percentage of
patients with dengue who were transferred to the study hospital
from our study health center varied between 11% and 36%, but
during 2009, the year where the revised WHO dengue
classification scheme was implemented in the cohort study, the
percentage of transferred cases rose to 83% (A. Balmaseda, G.
Kuan, E. Harris, unpublished data). The revised classification has
a specificity of 78.5% for detecting severe cases of dengue, which is
virtually identical to that of the traditional classification (75.5%),
with the exception that the revised classification scheme has a
significantly higher negative predictive value. This feature of the
revised classification may allow the clinician to better discern a
patient who does not have a severe case of dengue.
From the treating physician’s viewpoint, the revised classifica-
tion may be useful because it allows the patient to be classified and
treated in real-time, that is, during their hospital stay, whereas with
the traditional classification scheme, the majority of cases tended
to be retrospectively classified so as to detect the presence of the
four criteria that define severity (DHF/DSS). This is reflected in
the observed difficulty in correctly classifying the patient according
to the traditional classification schema, expressed by the low level
of agreement with the clinician’s diagnosis (kappa=0.46). Ideally,
one would hope for a classification that is both sensitive and
specific for detection of severe cases of dengue, in order to avoid
oversaturation of health units, especially at the secondary level, but
neither of the two classification schemes evaluated here possess
these characteristics. Choosing a highly sensitive test maximizes
the capture of severe cases, but requires subsequent evaluation
during the patients’ hospitalization to determine their real
condition.
The traditional WHO classification allows characterization of
the pathophysiology of severe cases of dengue as the syndrome of
DHF/DSS. This focus on a particular syndrome is useful for
investigating viral and immunological risk factors. For example, in
Table 6. Concordance
a between clinical diagnosis and
diagnosis by computer algorithm according to the traditional
WHO classification.
Traditional WHO
Classification
Clinical Diagnosis Algorithm Total
DF DHF DSS
DF 174 5 1 180
D H F 33 06
DSS 5 16 5 26
Total 182 24 6 212
aKappa=0.46, CI95%=0.38–0.55, p,0.001.
doi:10.1371/journal.pntd.0001397.t006
Table 7. Concordance
a between clinical diagnosis and
diagonsis by computer algorithm according to the revised
WHO classification.
Revised WHO
Classification
Clinical Diagnosis Algorithm Total
Dengue
without
Warning
Signs
Dengue
with
Warning
Signs
Severe
Dengue
Dengue without Warning Signs 13 15 2 30
Dengue with Warning signs 3 58 11 72
Severe Dengue 2 14 94 110
Total 18 87 107 212
aKappa=0.62, CI95%=0.53–0.71, p,0.001.
doi:10.1371/journal.pntd.0001397.t007
Table 8. Association between traditional and revised WHO
classifications for dengue severity and serotype, 2005–2010.
WHO
Classification Serotype p-value
a
DENV-1
N=45
N( % )
DENV-2
N=161
N( % )
DENV-3
N=287
N( % )
DENV-3 &
DENV-4
N=1
N( % )
Traditional
b
DF 33 (73.3) 79 (49.1) 229 (79.8) 1 (100) ,0.001
DHF 7 (15.6) 46 (28.6) 47 (16.4) 0
DSS 5 (11.1) 36 (22.3) 11 (3.8) 0
Revised
b
Dengue without
Warning Signs
2 (4.5) 5 (3.1) 20 (7.0) 0 0.104
Dengue with
Warning Signs
20 (44.4) 71 (44.1) 150 (52.2) 0
Severe Dengue 23 (51.1) 85 (52.8) 117 (40.8) 1 (100)
ap-value for Fisher’s exact test.
bIf the case of DENV-3 & DENV-4 is excluded, the p-value for Fisher’s exact test
for the traditional WHO classification is ,0.001 and for the revised WHO
classification, p=0.087.
doi:10.1371/journal.pntd.0001397.t008
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DHF/DSS; this information is useful for clinicians and public
health officials to keep in mind for future epidemics, as well as for
designing possible follow-up investigations. However, this associ-
ation was not observed when the new classification was used,
presumably because the definition of severe dengue is so broad.
DENV2 has been associated in this and numerous other studies
with the defining features of DHF/DSS [23,24] and with DHF/
DSS to a greater extent than other serotypes [24,25]. Therefore, it
is not surprising that DENV2 is significantly associated with
severity (DHF/DSS) using the previous classification scheme, but
not with the revised classification scheme, which is no longer
specific for DHF/DSS or the key clinical manifestations (e.g.,
thrombocytopenia, shock).
‘‘Severe dengue’’ and ‘‘Dengue with warning signs’’ are very
broad definitions that make it difficult to determine the
pathophysiology of the disease. Therefore, it is important to
analyze the frequency of warning signs and of severe manifesta-
tions, respectively, in order to obtain a clearer picture of the
disease profile. Similarly, the specific syndrome of plasma leakage
(DHF/DSS), so characteristic of the critical phase of dengue, is lost
in the new classification; thus, for studies of viral, host, and
immunological determinants of dengue pathogenesis, a more
specific definition than ‘‘severe dengue’’ will need to be
implemented. Additional implications of the new classification
scheme exist with respect to epidemiological surveillance, since the
traditional and revised categories are not equivalent and may
initially lead to a difficult transition. According to results obtained
in this study, we believe the revised classification is most useful for
the physician for the detection of severe cases of dengue, but its
utility in pathphysiological and epidemiological studies needs
further evaluation in future research.
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